Table 3.

Internal validation study of independent predictors of survival

VariablesRR for death (95% CI)P
Training data (randomly selected 50% of patients)
 Albumin < 3.5 g/dL1.58 (1.16–2.15)0.0035
 Number of metastatic sites > 21.42 (1.15–1.75)0.0012
 LDH > 618 IU/L1.74 (1.40–2.15)<0.0001
 Gastrointestinal tumor type1.68 (1.36–2.07)<0.0001
 ECOG PS ≥ 11.32 (1.05–1.66)0.0160
 Platelet > 440 K/UL1.40 (1.05–1.88)0.0230
 Prior treatment ≥ 31.40 (1.10–1.78)0.0063
Validation data (the remaining 50% of patients)
 Albumin < 3.5 g/dL1.69 (1.25–2.29)0.0006
 Number of metastatic sites > 21.26 (1.03–1.55)0.0260
 LDH > 618 IU/L1.83 (1.48–2.27)<0.0001
 Gastrointestinal tumor type1.42 (1.15–1.76)0.0010
 ECOG PS ≥ 11.32 (1.07–1.64)0.0110
 Platelet > 440 K/ULa1.35 (0.99–1.84)0.0540
 Prior treatment ≥ 3a1.23 (0.98–1.55)0.0730

Abbreviations: PS, performance status; RR, relative risk.

  • aElevated platelet levels (>440 K/UL) and ≥3 prior therapies are not statistically significant in the validation set and are therefore not included in our prognostic score.